


Annual Report 2008



Multiple Myeloma Research Consortium



**MMRC**

Multiple Myeloma  
Research Consortium

## Dear Friends:

---

Thanks to your support, 2008 was a landmark year for the Multiple Myeloma Research Consortium (MMRC). By staying focused on innovation, speed, and results, we achieved powerful milestones that are already making a real difference in patients' lives. In 2008, the MMRC:

- Welcomed Susan L. Kelley, MD, as our Chief Medical Officer. Dr. Kelley is an oncologist by training, and has more than 20 years of experience in clinical research and drug development within the pharmaceutical industry. Most recently, she served as Vice President of Global Clinical Development for Oncology at Bayer Healthcare Pharmaceuticals.
- Advanced seven new high-priority Phase I and Phase II clinical trials of novel compounds and combinations that may represent the next generation of multiple myeloma treatments.
- Accelerated by 30 to 40 percent the activation rate of clinical trials conducted through the MMRC, allowing patients to access potential new treatments an average of 100 days sooner. This incredible achievement underscores the power of our model in injecting speed and efficiency into the drug development process.
- Completed comprehensive analyses of 200 tissue samples through the MMRC Multiple Myeloma Genomics Initiative, positioning the effort to be the first to sequence the multiple myeloma genome in its entirety. Findings have already enabled us to identify several new therapeutic targets for the disease and will be used to help develop the next generation of treatments.

These successes are truly a testament to your generosity and to the incredible progress we can make with you by our side.

We are so grateful for your commitment.

Best regards,



Kathy Giusti  
Founder and CEO



## Financials

---

### Statements of Activities (Audited) Years Ended December 31, 2008 and 2007

	<b>2008</b>	<b>2007</b>
<b>Revenue</b>		
Contributions	\$ 6,411,750	\$ 4,817,812
In-kind donations	24,302	33,362
Interest income	20,543	79,759
Net assets released from restrictions	-	-
	<hr/>	<hr/>
<b>Total Revenue</b>	<b>6,456,595</b>	<b>4,930,933</b>
<b>Expenses</b>		
Program	6,128,219	6,384,408
Management and general expenses	133,953	378,722
Fund raising	-	95,330
	<hr/>	<hr/>
<b>Total expenses</b>	<b>6,262,172</b>	<b>6,858,460</b>
<b>Change in net assets</b>	<b>194,423</b>	<b>(1,927,527)</b>
	<hr/>	<hr/>
<b>Net assets, beginning of year</b>	<b>2,810,517</b>	<b>4,738,044</b>
	<hr/>	<hr/>
<b>Net assets, end of year</b>	<b>\$ 3,004,940</b>	<b>\$ 2,810,517</b>
	<hr/>	<hr/>



# MMRC

Multiple Myeloma  
Research Consortium

## Current Board of Directors

W. Dana LaForge, Chairman  
Kenneth C. Anderson, MD  
Karen Andrews  
Robert J. Beall, PhD  
Frank Douglas, PhD, MD  
Kathy Giusti  
Stephen Grand  
Eugene Grisanti  
Alan L. Heller  
Frederick H. Joseph  
Anthony K. Kesman  
Lori Marcus  
Gerald McDougall  
William S. McKiernan  
Mike Mortimer  
Charles B. Ortnier  
Edward Jay Phillips  
William Wilson, III  
Donna Zaccaro  
Meryl Zausner

## MMRC Member Institutions

Dana-Farber Cancer Institute  
H. Lee Moffitt Cancer Center  
& Research Institute  
Mayo Clinic Cancer Center  
City of Hope National Medical Center  
Emory University  
Hackensack University Medical Center  
Indiana University Simon Cancer Center  
Ohio State University  
Comprehensive Cancer Center  
Roswell Park Cancer Institute  
Saint Vincent Catholic  
Medical Centers of New York  
University Health Network  
(Princess Margaret Hospital)  
University of California, San Francisco  
University of Chicago  
University of Michigan  
Washington University

### Multiple Myeloma Research Consortium

383 Main Avenue, 5th Floor  
Norwalk, CT 06851  
Ph: (203) 229-0464